The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC).
Martin R. Stockler
Consultant or Advisory Role - Roche (U)
Felix Hilpert
Consultant or Advisory Role - Roche
Honoraria - Roche
Michael Friedlander
Consultant or Advisory Role - Roche
Madeleine King
Consultant or Advisory Role - Roche (U)
Other Remuneration - Roche
Lari B. Wenzel
No relevant relationships to disclose
Chee Lee
Consultant or Advisory Role - Roche (U)
Florence Joly
Consultant or Advisory Role - PharmaMar (U); Roche
Honoraria - PharmaMar; Roche
Nikolaus De Gregorio
No relevant relationships to disclose
Jose Angel Arranz Arija
Honoraria - Roche
Research Funding - Roche
Mansoor Raza Mirza
Consultant or Advisory Role - Roche
Roberto Sorio
No relevant relationships to disclose
Ulrich Freudensprung
Employment or Leadership Position - Roche
Vesna Sneller
Employment or Leadership Position - Roche
Gill Hales
Employment or Leadership Position - Roche
Stock Ownership - Roche
Eric Pujade Lauraine
Consultant or Advisory Role - Roche (U)